AIM Vaccine Co., Ltd. Class H (HK:6660) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
AIM Vaccine Co., Ltd., a leading supplier of rabies vaccines, has submitted a pre-application for marketing its innovative serum-free rabies vaccine, which has demonstrated excellent safety and immunogenicity in Phase III trials. This vaccine, free from animal serum, aims to reduce allergic reactions and is poised to be the first of its kind globally, marking a significant advancement in rabies prevention. The company has completed the necessary infrastructure for large-scale production, positioning itself to enhance vaccine quality and safety worldwide.
For further insights into HK:6660 stock, check out TipRanks’ Stock Analysis page.